

AGENDA
128TH Meeting of the
National Cancer Advisory Board
National Cancer Institute

TUESDAY, DECEMBER 2, 2003 - OPEN
Building 31, C Wing, Conference Room 10

8:00 a.m. - 8:10 a.m.

I. CALL TO ORDER, OPENING REMARKS, *and* Dr. Niederhuber
CONSIDERATION OF SEPTEMBER 2003 MINUTES

II. FUTURE BOARD MEETING DATES

Confirmed:

February 17-19, 2004	Tuesday, Wednesday, Thursday
June 1-3, 2004	Tuesday, Wednesday, Thursday
September 13-15, 2004	Monday, Tuesday, Wednesday
November 29 - December 1, 2004	Monday, Tuesday, Wednesday
February 15-17, 2005	Tuesday, Wednesday, Thursday
June 6-8, 2005	Monday, Tuesday, Wednesday
September 19-21, 2005	Monday, Tuesday, Wednesday
December 5-7, 2005	Monday, Tuesday, Wednesday

8:10 a.m. - 8:40 a.m.

III. DIRECTOR'S REPORT Dr. von Eschenbach

8:40 a.m. - 9:10 a.m.

IV. FISCAL 2004 BUDGET UPDATE Mr. Hartinger
Mr. Hazen

9:10 a.m. - 9:30 a.m.

V. PRESIDENT'S CANCER PANEL REPORT Dr. Leffall

9:30 a.m. - 9:45 a.m.

VI. LEGISLATIVE UPDATE Ms. Erickson

9:45 a.m. - 10:15 a.m.

VII. OVERVIEW: CENTER FOR STRATEGIC DISSEMINATION Dr. Maibach

10:15 a.m. – 10:20 a.m.

VIII. SPECIAL RECOGNITION

Dr. von Eschenbach
Dr. Niederhuber

10:20 a.m. - 10:35 a.m.

COFFEE BREAK

10:35 a.m. - 11:05 a.m.

IX. OVERVIEW: OFFICE OF COMMUNICATIONS

Ms. Castro
Ms. Bright

11:05 a.m. - 12:00 noon

X. NANOTECHNOLOGY STRATEGIC INITIATIVES

Dr. Barker
Dr. Ferrari

12:00 noon - 1:15 p.m.

WORKING LUNCH

- Update: Task Force on Advanced Biomedical Technology Initiative

Dr. Lander

1:15 p.m. - 4:05 p.m.

XI. PROGRAM REVIEW OF CENTER FOR CANCER RESEARCH

1:15 p.m. OVERVIEW

Dr. Barrett

1:30 p.m. FUNDAMENTAL DISCOVERIES IN CANCER

- Role of DNA Breaks in Genomic Instability and Cancer
- TGF-betas in Cancer Progression: Complex Roles and Therapeutic Opportunities

Dr. Nussenzweig

Dr. Wakefield

2:20 p.m. NOVEL APPROACHES IN CANCER DETECTION AND DIAGNOSIS

- Mapping Molecular Network Interconnections Using Protein Microarrays for Patient Tailored Therapy
- Oncologic Imaging: Anatomic, Functional and Molecular

Dr. Petricoin

Dr. Choyke

3:10 p.m. IMMUNOTHERAPY

- Integrating Immunotherapy into Cytotoxic Regimens: Pediatric Sarcomas as a Model Dr. Mackall
- Design, Development and Delivery of Recombinant Vaccines for the Therapy of Human Carcinomas Dr. Schlom

3:55 p.m. CONCLUDING REMARKS Dr. Barrett

4:05 p.m. - 4:20 p.m.

COFFEE BREAK

4:20 p.m.

ADJOURNMENT OF OPEN SESSION

TUESDAY, DECEMBER 2, 2003 - CLOSED

4:20 p.m. - 5:20 p.m.

XII. CLOSED SESSION

This portion of the meeting is being closed to the public in accordance with the provisions set forth in Sections 552b(c)(4), 552b(c)(6). Title 5 U.S. Code and 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2).

- INTRAMURAL SITE VISITS AND TENURE APPOINTMENTS
- PERSONNEL AND PROPRIETARY ISSUES

5:20 p.m.

ADJOURNMENT

WEDNESDAY, DECEMBER 3, 2003 - OPEN
Building 31, C Wing, Conference Room 10

8:00 a.m. - 10:00 a.m.

XIII. INTRAMURAL RE-ENGINEERING INITIATIVE Dr. Barrett

10:00 a.m. - 10:15 a.m.

COFFEE BREAK

10:15 a.m. - 10:35 a.m.

XIV. THINK TANK TASK FORCES AND
LONG RANGE SCIENTIFIC PLANNING

Dr. Singer

10:35 a.m. - 11:35 a.m.

XV. NATIONAL BIO-SPECIMEN NETWORK INITIATIVES

Dr. Barker

11:35 a.m. - 11:55 a.m.

XVI. BOARD STATUS REPORTS

- NCAB RETREAT REPORT
- SUBCOMMITTEE UPDATE(S)

Dr. Niederhuber
Members

11:55 a.m. – 12:00 noon

XVII. FUTURE AGENDA ITEMS

Members

12:00 noon

ADJOURNMENT

SPEAKERS

Anna Barker, Ph.D.
Deputy Director
Strategic Scientific Initiatives
National Cancer Institute, NIH
Bethesda, MD

J. Carl Barrett, Ph.D.
Director
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Ms. Mary Anne Bright
Acting Deputy Director
Office of Communications
National Cancer Institute, NIH
Bethesda, MD 20892-1928

Ms. Nelvis Castro
Acting Director
Office of Communications
National Cancer Institute, NIH
Bethesda, MD

Peter Choyke, M.D.
Chief
Magnetic Resonance Imaging
Diagnostic Radiology Department
National Institutes of Health
Bethesda, MD

Ms. Susan Erickson
Acting Director
Office of Policy Analysis and Response
National Cancer Institute, NIH
Bethesda, MD

Mauro Ferrari, Ph.D.
Edgar Hendrickson Professor of Biomedical Engineering
Professor of Internal Medicine
Division of Oncology
Associate Vice President
Health Sciences Technology and Commercialization
Davis Heart and Lung Research Institute
The Ohio State University
Columbus, OH

Mr. John Hartinger
Associate Director
Office of Budget and Financial Management
National Cancer Institute, NIH
Bethesda, MD

Mr. Stephen Hazen
Chief
Extramural Financial Data Branch
Office of Budget and Financial Management
National Cancer Institute, NIH
Bethesda, MD

Eric Lander, Ph.D.
Professor of Biology
Director
Whitehead Institute Center for Genome Research
Massachusetts Institute of Technology
Cambridge, MA

LaSalle D. Leffall, Jr., M.D.
Charles R. Drew Professor of Surgery
Department of Surgery
Howard University College of Medicine
Howard University Hospital
Washington, DC

Crystal L. Mackall, M.D.
Head
Immunology Section
Pediatric Oncology Branch
National Cancer Institute, NIH
Bethesda, MD

Edward Maibach, Ph.D.
Director
Center for Strategic Dissemination
National Cancer Institute, NIH
Bethesda, MD

Andre Nussenzweig, Ph.D.
Senior Investigator
Recombination Section
Experimental Immunology Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Emmanuel Frank Petricoin, Ph.D.
Co-Director
NCI- FDA Clinical Proteomics Program
Senior Principal Investigator
Center for Biologics Evaluation and Research
Food and Drug Administration
Bethesda, MD 20892

Jeffrey Schlom, Ph.D.
Chief
Laboratory of Tumor Immunology and Biology
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Dinah Singer, Ph.D.
Director
Division of Cancer Biology
National Cancer Institute, NIH
Bethesda, MD

Lalage Wakefield, D. Phil.
Head
Tumor Suppressor Group
Laboratory of Cell Regulation and Carcinogenesis
National Cancer Institute, NIH
Bethesda, MD